Zivo Bioscience (ZIVO) AI Stock Analysis

• Market Cap: $54.23M
• Dividend Yield: N/A
• Average Volume (3M): 529.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.52
• Revenue Growth: 398.55%
• EPS Growth: 8.27%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -4.35
• Shares Outstanding: 3,813,517
• 10 Day Avg. Volume: 517
• 30 Day Avg. Volume: 529
• PEG Ratio: <0.01
• Price to Book (P/B): -0.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.16
• Enterprise Value/Market Cap: 0.10
• Enterprise Value/Revenue: 13.24
• Enterprise Value/Gross Profit: 151.48
• Enterprise Value/Ebitda: -0.10
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 34 Underperform
• Price Target: ―

Zivo Bioscience faces significant financial challenges, including negative equity and cash flow issues, which are the primary factors in its low score. Despite some technical indicators showing neutrality, the company's negative valuation metrics further impact the score. Urgent financial restructuring is necessary for sustainability.

Positive Factors

Licensing Agreements

ZIVO is engaged in constructive discussions with two major global animal health companies regarding potential licensing agreements for ZIVO’s coccidiosis product.

Poultry Health Opportunities

Positive results from the avian flu study and plans for an additional trial are viewed favorably as it could expand ZIVO’s opportunities in poultry health.

Negative Factors

Balance Sheet Concerns

There is a risk that a deal does not come to fruition, combined with lingering concerns regarding the balance sheet and access to capital.

Capital Raising Challenges

Ongoing challenges of raising capital as an unlisted security is a concern.

Cash and Debt Situation

ZIVO had cash and equivalents of $159K and debt of $355K, and it is expected to burn an average of $1.7M per quarter through 2025, relying on private placements or high interest-rate loans for funding.

Zivo Bioscience Business Overview & Revenue Model

Company Description

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

How the Company Makes Money

Zivo Bioscience makes money by developing and licensing its proprietary algal bioactive compounds to companies in the nutrition, wellness, and animal health industries. The company's revenue streams largely consist of licensing fees, royalties, and collaborative research agreements. Through partnerships with manufacturers and distributors, Zivo capitalizes on its intellectual property by integrating its algal compounds into various consumer and animal products. The company may also engage in direct sales of its algal biomass or extracts to businesses looking to include these components in their product offerings. Key partnerships in these sectors help Zivo expand its market reach and contribute to its earnings.

Zivo Bioscience Financial Statement Overview

Summary

Zivo Bioscience is experiencing growth in revenue but is struggling with significant net losses and negative cash flows, indicating financial instability. The balance sheet reflects insolvency with negative equity, requiring urgent financial restructuring. The biotech industry is inherently risky, and the company needs to address its financial challenges to achieve sustainability.

Income Statement

Zivo Bioscience has shown revenue growth over the years, with a TTM revenue of $79,020 compared to $27,650 in the previous year, indicating a significant growth trajectory. However, the company continues to report substantial net losses, resulting in a negative net profit margin. The EBIT and EBITDA margins are negative, reflecting ongoing operational challenges and a lack of profitability.

Balance Sheet

The company's balance sheet is weak with a negative stockholders' equity, indicating insolvency. The debt-to-equity ratio cannot be accurately calculated due to negative equity. The equity ratio is negative due to liabilities exceeding assets, highlighting significant financial risk.

Cash Flow

Zivo Bioscience's cash flow statement reveals a consistent pattern of negative free cash flow, impacting liquidity. The operating cash flow to net income ratio is negative, showing poor cash generation relative to net losses. Although financing activities have provided some cash inflow, it is insufficient to cover operating cash outflows.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
121.50K	157.22K	27.65K	0.00	0.00	20.00K
	Gross Profit
36.45K	48.95K	11.61K	0.00	0.00	20.00K
	EBIT
-16.29M	-13.36M	-7.26M	-8.73M	-9.05M	-8.56M
	EBITDA
-16.29M	-13.36M	-7.26M	-8.73M	-9.05M	-550.05K
	Net Income Common Stockholders
-16.32M	-13.38M	-7.78M	-8.75M	-9.40M	-9.66M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
517.19K	1.54M	274.38K	1.80M	8.90M	137.86K
	Total Assets
1.33M	1.64M	555.72K	2.12M	8.99M	220.18K
	Total Debt
893.13K	254.36K	346.34K	445.18K	255.18K	5.36M
	Net Debt
375.95K	-1.29M	71.96K	-1.35M	-8.65M	5.22M
	Total Liabilities
335.91K	2.16M	2.76M	2.13M	2.95M	11.53M
	Stockholders Equity
-1.62M	1.53M	-2.21M	-10.62K	6.04M	-11.31M
Cash Flow		Free Cash Flow
-4.04M	-4.31M	-5.80M	-7.10M	-6.80M	-2.59M
	Operating Cash Flow
-4.04M	-4.31M	-5.80M	-7.10M	-6.80M	-2.59M
	Investing Cash Flow
0.00	0.00	0.00	0.00	0.00	0.00
	Financing Cash Flow
4.42M	5.58M	4.28M	-628.60K	15.57M	2.38M

Zivo Bioscience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 14.22
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZIVO, the sentiment is Negative. The current price of 14.22 is below the 20-day moving average (MA) of 15.99, below the 50-day MA of 16.26, and below the 200-day MA of 17.99, indicating a bearish trend. The MACD of -0.87 indicates Positive momentum. The RSI at 42.29 is Neutral, neither overbought nor oversold. The STOCH value of 38.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZIVO.

Zivo Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	64 Neutral	¥344.44B	10.52	-2.88%	2.62%	11.64%	-5.91%
SNGX	39 Underperform	$5.55M	―	-437.73%	―	―	57.83%
CTXR	38 Underperform	$12.07M	―	-60.06%	―	―	8.99%
OTLK	38 Underperform	$73.07M	―	<0.01%	―	―	-29.01%
ZIVO	34 Underperform	$54.23M	―	657.30%	―	398.55%	8.27%